1. No category

SLAS Asia 2015 Conference and Exhibition Program
Day 1, Thursday, 9 April
08:45-09:00
09:00-09:45
09:45-12:45
09:45-10:15
10:15-10:45
SLAS Opening Remarks
Keynote 1: Going Fishing for Better Medicines
K. Barry Sharpless, Ph.D., Nobel Prize Laureate, W. M. Keck Professor of Chemistry, The
Scripps Research Institute
Session 1: Leading Science for Small Molecules Drug Discovery
Co-chairs:
Jonathan Connick, Ph.D., Executive Director, Head External in Vitro Pharmacology.
Site Head, EDDS and PCD China, Merck & Co., Inc.
Bin Li, Ph.D., R&D Director, AbbVie China R&D Center
Discovery of GPR119 Agonist from Hoodia
Xin Xie, Ph.D., Principle Investigator, Shanghai Institute of Materia Medica, Chinese
Academy of Sciences; Deputy Director, Chinese National Center for Drug Screening
Sponsored by:
Phenotypic Drug Discovery and Target Deconvolution
Jing Li, Ph.D., Director of Pharmacology; Department of Screening and Protein Science;
Merck Research Laboratories (MRL)
10:45-11:15
Break in Exhibit Hall
11:15-11:45
Discovery of HIV Integrase Inhibitors
John Wai, Ph.D., Vice President of Medicinal Chemistry, WuXi AppTec (Shanghai)
11:45-12:45
12:45-14:30
12:45-14:30
Panel Discussion: Leveraging Technology and Tools to Enable Drug Discovery
Moderator: Jonathan Connick, Ph.D., Executive Director, Head External in Vitro
Pharmacology. Site Head, EDDS and PCD China, Merck & Co., Inc.
Panelist:
Jing Li, Ph.D., Director of Pharmacology; Department of Screening and Protein Science;
Merck Research Laboratories (MRL)
Xuehai Tan, Ph.D., CEO & President, HD Biosciences Co., Ltd.
Joe Gu, Ph.D., LST APAC VP GM, Perkin Elmer
Xin Xie, Ph.D., Principle Investigator, Shanghai Institute of Materia Medica, Chinese
Academy of Sciences; Deputy Director, Chinese National Center for Drug Screening
Lunch in Exhibit Hall
Posters
1|P a g e
13:45-14:30
14:30-17:30
14:30-15:00
15:00-15:30
15:30-16:00
Exhibitor Tutorial 1:
Location: Nanjing Room, Level 5
Exhibitor Tutorial 2:
Location: Suzhou Room, Level 5
Sponsored by
Sponsored by
Session 2: Natural Product Drug Discovery & Synthetic Biology
Co-chairs:
Bing Xie, Ph.D., Managing Director, Asia Pacific for Cisbio Bioassays
Mike Zhang, Ph.D., Associate Sales Director, BD Biosciences
Discovery of NITD609 as Antimalarial: From Natural Product-like Lead to Clinical
Candidate
Bin Zou, Ph.D., Senior Medicinal Chemist, Novartis Institute for Tropical Diseases
(Singapore)
HTS Hits - Which Should You Discard, and Why?
Jonathan Baell, Ph.D., Research Professor, Medicinal Chemistry, Monash Institute of
Pharmaceutical Science
Break in Exhibit Hall
Anti-infective and Anti-tumor Natural Products Discovery and Biosynthesis from Marine
Actinomycetes
16:00-16:30
16:30-17:00
17:00-17:30
17:30-19:00
Jianhua Ju, Ph.D., Professor, South China Sea Institute of Oceanology, Chinese
Academy of Sciences; Director, Guangdong Key Laboratory of Marine Materia Medica;
Deputy Director, CAS Key Laboratory of Marine Bio-resources and Ecology
Anti-infectious Natural Products from Marine-derived Microbes
Xueting Liu, Ph.D., Associate Professor, CAS Key Laboratory of Pathogenic Microbiology
& Immunology
Technology Innovation in Drug Discovery to Fight Global Disease
Hakim Djaballah, Ph.D., Chief Executive Office, Insitut Pasteur Korea, Pankyo, Korea
Member, Board of Directors, Qurient, Pankyo, Korea Professor of Chemical Biology,
University of Science & Technology, Daejeon, Korea
Reception
2|P a g e
Day 2, Friday, 10 April
08:45-09:00
Welcome Speech - Biologics Innovation Group (BiG) Annual Conference
Biao Jiang, Ph.D.,
Vice President of Shanghai Advanced Research Institute, CAS;
Executive Director of Shanghai Institute for Advanced Immunochemical Studies; Professor
09:00-12:30
Part I
09:00-09:45
09:45-10:15
10:15-10:45
Part II
10:45-11:15
11:15-11:45
Session 3: The Scientific Frontier of Biological Discovery
Co-chairs:
Ying Yang, MBA, Founder & CEO, LBD Life Sciences Ltd.; Asia Council Chair, Society
for Laboratory Automation and Screening (SLAS)
Biao Jiang, Ph.D., Vice President of Shanghai Advanced Research Institute, CAS;
Executive Director of Shanghai Institute for Advanced Immunochemical Studies;
Professor
Keynote 2: Counteract the Emerging Infectious Diseases with Therapeutic
Antibodies: A Lesson from the Influenza and Ebola Infections
George Fu Gao, Ph.D., Director & Professor, Key Laboratory of Pathogenic
Microbiology and Immunology, Institute of Microbiology, Chinese Academy of
Sciences; Vice-President, Beijing Institutes of Life Science, Chinese Academy of
Sciences; Deputy Director-General, Chinese Center for Disease Control and
Prevention (China CDC); Academicians of Chinese Academy of Sciences
Systems Approach to Translational Medicine
Genhong Cheng, Ph.D., Director, Suzhou Institute of Systems Medicine, Chinese
Academy of Medical Sciences; Professor, Department of Microbiology, Immunology
& Molecular Genetics, University of California Los Angeles
Break in Exhibit Hall
Co-Chairs:
Guang Yang, Ph.D., Vice Director, Shanghai Institute for Advanced Immunochemical
Studies, ShanghaiTech University
Mingqiang Zhang, Ph.D., General Manager & Legal Representative, Amgen
Biopharmaceutical Research and Development (Shanghai) Company Ltd.
Therapeutic Antibody Discovery and Lead Selection
Yan Wu, Ph.D., Associate Director of Antibody Discovery and Principal Scientist,
Genentech
Feature Talk: Case Study-NIBS’s Technology Transfer
Xiaodong Wang, Ph.D., Director and Investigator, National Institute of Biological
Sciences, Beijing (NIBS); Foreign Academicians of Chinese Academy of Sciences;
Member of the National Academy of Sciences, USA
11:45-12:30
Panel Discussion: How Academia and Industry Can Collaborate More Efficiently for
Commercialization of Scientific Findings
Moderator: Chengbin Wu, Ph.D., CSO and President of R&D, Shanghai CP Guojian
Pharmaceutical Co., Ltd.
Panelist:
Xiaodong Wang, Ph.D., Director and Investigator, National Institute of Biological
Sciences, Beijing (NIBS) ; Foreign Academicians of Chinese Academy of Sciences,
Member of the National Academy of Sciences, USA
Mingqiang Zhang, Ph.D., General Manager & Legal Representative, Amgen
Biopharmaceutical Research and Development (Shanghai) Company Ltd.
Fritjof Linz, Ph.D., VP Head of Biologics CMC and Business Development,
3|P a g e
ChemPartner
Biao Jiang, Ph.D., Vice President of Shanghai Advanced Research Institute, CAS;
Executive Director of Shanghai Institute for Advanced Immunochemical Studies; Professor
Guanhua Du, Ph.D., Deputy Director, Institute of Material Medica, Chinese Academy of
Medical Sciences & Peking Union Medical College; President, Chinese Pharmacological
Society
12:30-14:00
12:30-14:00
13:15-14:00
14:00-17:45
Lunch in Exhibit Hall
Posters
Exhibitor Tutorial 3
Location: Nanjing Room, Level 5
Exhibitor Tutorial 4
Location: Suzhou Room, Level 5
Sponsored by
Sponsored by
Session 4: ADC - From Technology, Process, Discovery, to Development
Co-chairs:
Xueming Qian, Ph.D., Chairman & CEO, Mabspace Biosciences Co., Ltd.
Fritjof Linz, Ph.D., VP Head of Biologics CMC and Business Development,
ChemPartner
14:00-14:30
The Antibody-Drug Conjugates for Cancer Therapy: Deliver the Promise
Weikang Tao, Ph.D., CEO, Shanghai HengRui Medicine Co., Ltd., R&D Center
14:30-15:00
Site Specific Conjugation: Improvement of ADC Homogeneity and Druggability
Properties
Bruce Nianhe Han, Ph.D., CSO, NewBio Therapeutics
15:00-15:30
R&D of Next-generation ADCs Based on LDC Technology
Gang Qin, Ph.D., Cofounder & CEO, GeneQuantum Healthcare (Suzhou) Co., Ltd.
15:30-16:00
Biological Characterization of Antibody Drug Conjugates
Mary Hu, Ph.D., CEO, Shanghai Miracogen Inc.
16:00-16:30
Break in Exhibit Hall
16:30-17:00
17:00-17:30
17:30-17:45
A New Generation of Antibody-drug Conjugates for the Targeted Treatment of
Cancer
Robert Yongxin Zhao, Ph.D., CEO & Chairman, Hangzhou DAC Biotech Co., Ltd.
Developing a Novel ADC for Global Market via Innovative Three-party
Collaboration
Chris Chen, Ph.D., Senior Vice President and Chief Technology Officer for Biologics
Service, Wuxi AppTec Co Ltd.
Closing Remarks
4|P a g e